1. European Medicines Agency. Kaletra (lopinavir/ritonavir). Annex I: Summary of product characteristics. 2009. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000368/human_med_000867.jsp&mid=WC0b01ac058001d124 . Accessed 10 Feb 2013.
2. Kumar GN, Jayanti V, Lee RD, et al. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos. 1999;27:86–91.
3. Elens L, Yombi JC, Lison D, et al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics. 2009;10:1589–97.
4. Lubomirov R, Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20:217–30.
5. Gupta SK, Rosenkranz SL, Cramer YS, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22:1919–27.